The prognostic importance of prostate specific antigen in the monitorisation of patients undergoing maximum androgen blockade for metastatic prostate cancer

By Kiper Ahmet   Yiğitbası Orhan   Imamoglu Abdurrahim   Tuygun Can   Turan Celaleddin  

International Urology and Nephrology, Vol. 38, Iss. 3-4, 2006-12 ,pp. : 571-576

Springer Publishing Company

Access to resources Recommend Favorite

Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the ''European organization for research and treatment of cancer'' (EORTC) protocol 30892

By Schroder F.   Whelan P.   De Reijke T.   Kurth K.   Pavone M.   Mattelaer J.   Van Velthoven R.   Dubois M.   Collete L.  

European Urology Supplements, Vol. 2, Iss. 1, 2003-02 ,pp. : 188-188

Elsevier

Access to resources Recommend Favorite

Metastatic prostate cancer with normal level of serum prostate-specific antigen

By Nishio R.   Furuya Y.   Nagakawa O.   Fuse H.  

International Urology and Nephrology, Vol. 35, Iss. 2, 2003-01 ,pp. : 189-192

Springer Publishing Company

Access to resources Recommend Favorite

Improving survival for patients with prostate cancer diagnosed in the prostate-specific antigen era

By Gilliland F.D.   Hunt W.C.   Key C.R.  

Urology, Vol. 48, Iss. 1, 1996-07 ,pp. : 67-71

Elsevier

Access to resources Recommend Favorite

Impact of prostate-specific antigen screening on prostate cancer

By Zincke H.  

Urology, Vol. 47, Iss. 5, 1996-05 ,pp. : 783-783

Elsevier

Access to resources Recommend Favorite